PRRT4 Inhibitors
PRRT4 inhibitors represent a chemical class specifically targeting the protein PRRT4, which stands for Proline-Rich Transmembrane Protein 4. These inhibitors are small molecules designed to modulate the activity of PRRT4, a protein that has significant influence over various intracellular processes. The structural features of PRRT4 inhibitors typically allow them to interact with specific binding sites on the protein, thereby altering its function or activity. These inhibitors often contain diverse chemical motifs such as aromatic rings, heterocyclic structures, or specific side chains designed to enhance their affinity and selectivity towards PRRT4. Because PRRT4 has a proline-rich domain, these inhibitors often exploit this unique structural feature to achieve binding specificity, which may involve hydrogen bonding, hydrophobic interactions, or other non-covalent forces that stabilize the inhibitor-protein complex.
The development and characterization of PRRT4 inhibitors also involve significant focus on their chemical properties, such as solubility, stability, and the ability to permeate cell membranes to reach their intracellular target effectively. Structure-activity relationship (SAR) studies are a critical aspect of designing these inhibitors, as they help to refine the molecular structure for optimal binding affinity and minimal off-target interactions. Researchers often employ computational modeling, biochemical assays, and crystallographic studies to understand how these inhibitors interact with PRRT4 at a molecular level. Furthermore, the bioavailability and chemical modifications of these inhibitors are frequently examined to ensure they retain their inhibitory activity within a biological system. Overall, PRRT4 inhibitors are a highly specialized group of compounds, tailored to modulate PRRT4 activity through precise molecular mechanisms and binding interactions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
THZ1 | 1604810-83-4 | sc-507542 | 1 mg | $95.00 | ||
THZ1, a covalent CDK7/CDK12/CDK13 inhibitor, directly targets CDK7. Given the interaction between CDK7 and PRRT4, THZ1 indirectly influences PRRT4 by inhibiting CDK7-mediated phosphorylation. THZ1 disrupts the phosphorylation events associated with PRRT4, potentially altering its functional role in cellular processes. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib, a pan-CDK inhibitor, directly targets multiple cyclin-dependent kinases, including CDK9. Its impact on CDK9-mediated phosphorylation indirectly affects PRRT4, which interacts with CDK9. Dinaciclib disrupts the phosphorylation events associated with PRRT4, potentially modifying its functional role in cellular processes. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol, a pan-CDK inhibitor, directly targets multiple cyclin-dependent kinases, including CDK9. Its impact on CDK9-mediated phosphorylation indirectly influences PRRT4, which interacts with CDK9. Flavopiridol disrupts the phosphorylation events associated with PRRT4, potentially altering its functional role in cellular processes. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine, a pan-CDK inhibitor, directly targets multiple cyclin-dependent kinases, including CDK9. Its impact on CDK9-mediated phosphorylation indirectly affects PRRT4, which interacts with CDK9. Seliciclib disrupts the phosphorylation events associated with PRRT4, potentially modifying its functional role in cellular processes. | ||||||
Zotiraciclib | 937270-47-8 | sc-507450 | 10 mg | $202.00 | ||
This compound, also called TG-02, a multi-CDK inhibitor, directly targets multiple cyclin-dependent kinases, including CDK9. Its impact on CDK9-mediated phosphorylation indirectly influences PRRT4, which interacts with CDK9. TG-02 disrupts the phosphorylation events associated with PRRT4, potentially altering its functional role in cellular processes. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032, a CDK inhibitor, directly targets multiple cyclin-dependent kinases, including CDK9. Its impact on CDK9-mediated phosphorylation indirectly affects PRRT4, which interacts with CDK9. SNS-032 disrupts the phosphorylation events associated with PRRT4, potentially modifying its functional role in cellular processes. | ||||||
R547 | 741713-40-6 | sc-364596 sc-364596A | 2 mg 5 mg | $375.00 $395.00 | ||
R547, a multi-CDK inhibitor, directly targets multiple cyclin-dependent kinases, including CDK9. Its impact on CDK9-mediated phosphorylation indirectly influences PRRT4, which interacts with CDK9. R547 disrupts the phosphorylation events associated with PRRT4, potentially modifying its functional role in cellular processes. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438, a multi-CDK inhibitor, directly targets multiple cyclin-dependent kinases, including CDK9. Its impact on CDK9-mediated phosphorylation indirectly influences PRRT4, which interacts with CDK9. AZD5438 disrupts the phosphorylation events associated with PRRT4, potentially altering its functional role in cellular processes. | ||||||